PURE Bioscience Q3 net product sales down 18% YoY to $406K; net loss widens to $876K

PURE BIOSCIENCE, INC.

2024-Q3 EPS reported -$0.03 revenue$1,269,000

Net product sales $406K in Q3 FY2023 vs $497K prior year, down 18% on decreased distribution sales.
Q3 net loss $876K vs $760K prior year; net loss per share flat at ($0.01).
Nine-month net product sales $1.27M vs $1.41M; net loss $2.93M vs $2.26M prior year.
CEO cites key distributor downturn; food division sales partially offset; new sales program initiated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PURE BIOSCIENCE, INC. reported the fiscal third quarter ended April 30, 2023 results: revenue $406,000, net income $876,000, EPS ($0.01).

Period: the fiscal third quarter ended April 30, 2023
Revenue: $406,000
Net income: $876,000
EPS: ($0.01)
Result: reported results

Exact text from the filing

Net product sales were $406,000 and $497,000 for the fiscal third quarters ended April 30, 2023 and 2022, respectively.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PURE BIOSCIENCE, INC. reported the nine months ended April 30, 2023 results: revenue $1,269,000, net income $2,929,000, EPS ($0.03).

Period: the nine months ended April 30, 2023
Revenue: $1,269,000
Net income: $2,929,000
EPS: ($0.03)
Result: reported results

Exact text from the filing

Net product sales were $1,269,000 and $1,409,000 for the nine months ended April 30, 2023 and 2022, respectively.

View on SEC.gov

Browse all earnings releases →

PURE BIOSCIENCE, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-021231

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.